FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Amir IravaniMedhat M OsmanAlison M WepplerRoslyn WallaceAnna GalliganArian LasockiMorgan O HunterTim AkhurstMichael S HofmanPeter K H LauDamien KeeGeorge Au-YeungShahneen SandhuRodney J HicksPublished in: European journal of nuclear medicine and molecular imaging (2020)
FDG-PET/CT response evaluation predicts the long-term outcome of patients treated with first-line combination-ICIs. Long-term treatment response monitoring for detection of extracranial secondary progression is feasible by FDG-PET/CT. Beyond response assessment, FDG-PET/CT frequently detects clinically relevant irAEs, which may involve multiple systems contemporaneously or at various time-points and may precede clinical diagnosis.